La Jolla Pharmaceutical Co. buy melinda
Startpreis
25.10.18
/
50%
16,08 ?
Kursziel
30.10.19
31,57 €
Rendite (%)
0,00 %
Endpreis
30.10.19
-
Zusammenfassung
Diese Einschätzung wurde am 30.10.19 mit einem Endkurs von - beendet. Unverändert schloss die BUY Einschätzung von melinda zu La Jolla Pharmaceutical Co.. melinda hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
Name | 1W | 1M | 1J | 3J |
---|---|---|---|---|
La Jolla Pharmaceutical Co. | - | - | - | - |
iShares Core DAX® | -0,68 % | 1,89 % | 15,37 % | 17,16 % |
iShares Nasdaq 100 | 0,33 % | 4,63 % | 29,82 % | 56,19 % |
iShares Nikkei 225® | -1,49 % | -2,36 % | 7,67 % | 3,63 % |
iShares S&P 500 | -0,52 % | 2,32 % | 25,46 % | 46,45 % |
Kommentare von melinda zu dieser Einschätzung
In der Diskussion La Jolla Pharmaceutical Co. diskutieren
SecteurRecherche biotechnologique et médicale Agenda 24/10 Publication de résultats
Operates as a biopharmaceutical company
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases.
Its products includes LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb.
LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone.
The LJPC-30Sa and LJPC-30Sb are the next generation gentamicin derivatives, which is an antibiotic for kidney toxicity.
The firm also provides GIAPREZA, angiotensin II which increases blood pressure in adults with septic and other distributive shock.
The company was founded in 1989 and is headquartered in San Diego, CA.
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases.
Its products includes LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb.
LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone.
The LJPC-30Sa and LJPC-30Sb are the next generation gentamicin derivatives, which is an antibiotic for kidney toxicity.
The firm also provides GIAPREZA, angiotensin II which increases blood pressure in adults with septic and other distributive shock.
The company was founded in 1989 and is headquartered in San Diego, CA.
Nombre d'employés : 309 personnes.
Es gibt keinen Handelsplatz
Buy closed
Beendete Einschätzungen von melinda zu La Jolla Pharmaceutical Co.
La Jolla Pharmaceutical Co.
Startkurs
Kursziel
Rendite (%)
34,47 ?
04.02.18
04.02.18
39,60 €
06.08.18
06.08.18
-10,97 %
06.08.18
06.08.18
La Jolla Pharmaceutical Co.
Startkurs
Kursziel
Rendite (%)
27,15 ?
22.12.17
22.12.17
72,16 €
29.12.17
29.12.17
7,84 %
29.12.17
29.12.17
La Jolla Pharmaceutical Co.
Startkurs
Kursziel
Rendite (%)
29,10 ?
29.08.17
29.08.17
72,16 €
29.08.17
29.08.17
7,19 %
29.08.17
29.08.17
La Jolla Pharmaceutical Co.
Startkurs
Kursziel
Rendite (%)
22,65 ?
12.04.17
12.04.17
28,86 €
21.04.17
21.04.17
11,91 %
21.04.17
21.04.17